Founded in March, 2009, TAXIS Pharmaceuticals is focused on the discovery and development of pharmaceuticals targeting multidrug-resistant bacterial pathogens that constitute a worldwide therapeutic category estimated to exceed $30B in annual sales revenues. The initial series of proprietary lead candidates, referred to as the azachryseniums (AZCs), display in vitro activity that is superior to current standards of care for a broad range of Gram-positive bacterial pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE).